Rigel Pharmaceuticals, Inc.
RIGL
$41.50
-$0.49-1.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 59.61M | 11.45M | 14.34M | 12.42M | -1.03M |
| Total Depreciation and Amortization | 607.00K | 604.00K | 604.00K | 611.00K | 613.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.96M | 3.13M | 1.76M | 2.55M | 2.37M |
| Change in Net Operating Assets | 7.27M | -16.08M | -2.20M | 6.10M | -1.65M |
| Cash from Operations | 30.54M | -893.00K | 14.50M | 21.68M | 302.00K |
| Capital Expenditure | -- | -- | -26.00K | -10.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 72.00K | 26.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -23.28M | -10.55M | -10.96M | 3.79M | 10.93M |
| Cash from Investing | -23.28M | -10.55M | -10.91M | 3.80M | 10.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 418.00K | 484.00K | 1.47M | 158.00K | 252.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -10.00M | -1.00M |
| Cash from Financing | 418.00K | 484.00K | 1.47M | -9.84M | -752.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.68M | -10.96M | 5.05M | 15.64M | 10.48M |